Raymond James sees potential for beats across biopharma coverage By Investing.com

Raymond James preview says Insmed’s Symphony data is tracking favorably and could support sequential launch growth into 2Q results.

Potentially positive reaction if 2Q results align with the “sequential launch growth” setup.

The article provides a specific thesis tied to 2Q results, but it is still an earnings preview rather than a new reported datapoint.

Raymond James highlights a 2Q Tyvaso print of about $480M to $490M as the key test for sequential revenue growth.

If Tyvaso revenue meets or exceeds the $480M to $490M threshold, sentiment likely improves; below it could pressure shares.

The article specifies a concrete revenue range and explains what it would imply for demand recovery and franchise erosion.

Raymond James says Jazz Pharmaceuticals could deliver its first beat and raise, with guidance potentially supported even if revenue growth slows to ~2% YoY.

Moderately positive skew if 2Q results support the beat/raise narrative.

The preview includes quantitative growth framing and a PDUFA date, but it is not a reported earnings print.

Raymond James argues the market undervalues Ionis’s Tryngolza sHTG launch versus focus on CARDIO-TTRansform’s topline miss.

Likely muted near-term reaction, but improved longer-term sentiment if Tryngolza traction is evident.

It provides a specific analyst view on market mispricing and expected reaction, but no new clinical/commercial datapoint is disclosed.

Raymond James expects PTC Therapeutics could beat and raise if 2Q sales print $150M to $160M, implying first-half sales around $275M to $285M.

Positive if 2Q sales land in or above the $150M to $160M band; negative if materially below.

The article gives explicit numeric thresholds and links them to beat-and-raise mechanics.

Raymond James notes Tonix expanded commercial coverage to about 52 million lives via two GPO agreements plus broad Medicaid coverage.

Potentially positive, but magnitude depends on whether conversion metrics improve in upcoming earnings.

This is a concrete commercial expansion, but the article does not provide performance data showing conversion yet.

Raymond James says Milestone Pharmaceuticals’ YTD weakness reflects overly linear extrapolation of Cardamyst launch updates, expecting trajectory to exceed expectations.

Could support a rebound if prescription growth exceeds the implied steady 100 MoM assumption.

The article is largely interpretive and does not provide new reported metrics, only an analyst expectation framework.